Bio-Rad Opens European headquarters in Basel, Switzerland, in April 2017
In April, Bio-Rad Laboratories, Inc., a global provider of life science research and clinical diagnostic products opened a facility in Basel, Switzerland. The new site will serve as a European headquarters for the company with administration offices and other areas that include research and development, purchasing, sales, and distribution. Bio-Rad was founded in 1952 and is based in Hercules, California, and has offices and facilities around the world. In 2017, embarking on its 65th year of operation, Bio-Rad’s global network of over 8,250 employees and operations are helping people live longer, healthier lives.
The California-based company is joining a growing number of US biotech companies such as Ultragenyx, Roivant Sciences and Singulex that have recently opened their European and global headquarters in Basel, Switzerland.
Bio-Rad is among the top five life science companies in the world, providing instruments, software, consumables, reagents, and content for the areas of cell biology, gene expression, protein purification, protein quantitation, drug discovery and manufacture, food safety, and science education. The company’s products and solutions are based on technologies to separate, purify, identify, analyze, and amplify biological materials such as antibodies, proteins, nucleic acids, cells, and bacteria.
As a leading global provider of in-vitro diagnostics supplies, Bio-Rad’s diagnostic products and systems leverage a broad range of technologies and deliver high-value clinical information in the blood transfusion, diabetes monitoring, autoimmune, and infectious disease testing markets. These products are used to support the diagnosis, monitoring, and treatment of diseases and other medical conditions.
Share this article
You might also be interested in
A research project is investigating the improvement in the condition of patients who have been hospitalized due to COVID-19. docdok.health based in Basel is contributing the smartphone app for the project.Read More
The Allschwil-based pharmaceutical company Idorsia receives a payment of 45 million US dollars as part of an agreement with Neurocrine Biosciences and shall also be entitled to claim milestone payments in future. Neurocrine has exercised a licensing option for a drug developed by Idorsia to treat epilepsy..Read More
Roche has received Emergency Use Authorization in the USA for an antibody test in connection with the novel coronavirus. The tests are already being distributed around the world. In May, production capacities are to already be scaled up to the high double-digit million area.Read More
Basel is valued as a location for company headquarters. In a rating from the fDi Intelligence platform of the Financial Times, Basel achieves eighth place in Europe. No other Swiss city does better.Read More
The investment and innovation promotion agency Basel Area Business & Innovation, previously known as BaselArea.swiss, can look back on a successful year in 2019. In this regard, positive developments in the healthtech sector and in Switzerland Innovation Park Basel Area stand out.Read More
The University Hospital Basel is the first Swiss hospital to have treated two Covid-19 patients with the plasma from a patient who has recovered from the virus, which means that they are receiving the appropriate antibodies. This method is a potential therapeutic option.Read More